. Author manuscript; available in PMC: 2013 Jun 3.

Published in final edited form as: Arch Intern Med. 2009 Oct 12;169(18):1684–1691. doi: 10.1001/archinternmed.2009.303

Table 2.

Prevalence and Relative Risk of Breast Tenderness at First Annual Follow-up by Randomization Assignment in the WHI E + P Trial (n=16608¹); all women and stratified by breast tenderness at baseline

	CEE+MPA		Placebo		RR²	(95% CI)	P-value³
	N	(%)⁴	N	(%)
All	3086/7808	(39.5)	1230/7464	(16.5)	2.40	(2.26, 2.54)	<0.001

							<0.001
No breast tenderness at baseline	2477/6868	(36.1)	770/6555	(11.8)	3.07	(2.85, 3.30)
Breast tenderness at baseline	589/895	(65.8)	448/859	(52.2)	1.26	(1.17, 1.37)

95 participants missing baseline breast tenderness data only, 1303 participants with missing year 1 data, and 33 participants missing both baseline and year 1 data.

Relative risk of breast tenderness at 12-month follow-up from a generalized linear model.

P-values for main effect of treatment (boldface) and for interaction between treatment assignment and baseline breast tenderness.

⁴

Percent reporting breast tenderness at 12-month follow-up.